Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Bowie Alfred Lloyd Jr. — Eikon Therapeutics, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / Bowie Alfred Lloyd Jr.

Bowie Alfred Lloyd Jr.

Chief Financial Officer at Eikon Therapeutics, Inc. · on record since Mar 4, 2026

Insider trading activity of Bowie Alfred Lloyd Jr.

Transactions on record: 1; since Mar 4, 2026

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Mar 4, 2026

Figures computed from official regulatory filings — methodology.

Companies where Bowie Alfred Lloyd Jr. has traded

Eikon Therapeutics, Inc.1 tx · Mar 4, 2026

Track record of Bowie Alfred Lloyd Jr.

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Bowie Alfred Lloyd Jr.

Co-insiders of Bowie Alfred Lloyd Jr.

Baynes Roy D.Eikon Therapeutics, Inc.
Chen LeonEikon Therapeutics, Inc.
Column Group IV-A, LPEikon Therapeutics, Inc.
Column Group IV GP, LPEikon Therapeutics, Inc.
Column Group IV, LPEikon Therapeutics, Inc.
Column Group Opportunity III GP, LPEikon Therapeutics, Inc.
Column Group Opportunity III, LPEikon Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Foresite Capital Fund IV, L.P.Eikon Therapeutics, Inc.

Foresite Capital Fund V, L.P.Eikon Therapeutics, Inc.

Foresite Capital Management IV, LLCEikon Therapeutics, Inc.

Foresite Capital Management V, LLCEikon Therapeutics, Inc.

Foresite Capital Opportunity Fund V, L.P.Eikon Therapeutics, Inc.

Foresite Capital Opportunity Management V, LLCEikon Therapeutics, Inc.

Foresite Capital VI-A, LLCEikon Therapeutics, Inc.

Foresite Capital VI-A Management, LLCEikon Therapeutics, Inc.

Francisco Ma. FatimaEikon Therapeutics, Inc.

FRAZIER KENNETH CEikon Therapeutics, Inc.

Hebert PeterEikon Therapeutics, Inc.

Huffines Robert LutherEikon Therapeutics, Inc.

Klobuchar Michael AEikon Therapeutics, Inc.

Kutzkey TimEikon Therapeutics, Inc.

Lux Co-Invest Opportunities II, L.P.Eikon Therapeutics, Inc.

Lux Total Opportunities, L.P.Eikon Therapeutics, Inc.

Lux Venture Partners V, LLCEikon Therapeutics, Inc.

Lux Ventures V, L.P.Eikon Therapeutics, Inc.

Meline David WEikon Therapeutics, Inc.

PERLMUTTER ROGER MEikon Therapeutics, Inc.

Svennilson PeterEikon Therapeutics, Inc.

TCG Opportunity III GP, LLCEikon Therapeutics, Inc.

Thorner Benjamin BrunoEikon Therapeutics, Inc.

Wolfe JoshEikon Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Eikon Therapeutics, Inc.	Mar 4, 2026	AwardD	67,044	0.00 USD	$0	SEC